Literature DB >> 11564071

Unrelated cord blood transplantation for adult patients with myelodysplastic syndrome-related secondary acute myeloid leukaemia.

J Ooi1, T Iseki, H Nagayama, A Tomonari, K Ito, N Shirafuji, A Tojo, K Tani, S Asano.   

Abstract

Seven adult patients with myelodysplastic syndrome (MDS)-related secondary acute myeloid leukaemia (AML) were treated with total body irradiation (TBI), cytosine arabinoside (Ara-C) and cyclophosphamide (CY), followed by unrelated human leucocyte antigen (HLA)-mismatched cord blood transplantation (CBT). Granulocyte colony-stimulating factor (G-CSF) was infused continuously from 12 h before until the end of Ara-C therapy to enhance the antileukaemia effect of Ara-C. Five patients are alive and free of disease at 7-31 months after transplantation. These preliminary results suggest that adult MDS-related secondary AML patients without suitable related or unrelated bone marrow donors should be considered as candidates for CBT.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11564071     DOI: 10.1046/j.1365-2141.2001.03049.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  2 in total

1.  Using related donors other than genotypically HLA-matched siblings in allogeneic hematopoietic stem cell transplantation for hematologic disease: a single institution experience in Japan.

Authors:  Akira Tomonari; Tohru Iseki; Jun Ooi; Satoshi Takahashi; Koji Ishii; Tsutomu Takahashi; Motohiro Shindo; Fumitaka Nagamura; Kaoru Uchimaru; Hitomi Nagayama; Naoki Shirafuji; Arinobu Tojo; Kenzaburo Tani; Shigetaka Asano
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  Human umbilical cord blood progenitors: the potential of these hematopoietic cells to become neural.

Authors:  Ning Chen; Jennifer E Hudson; Piotr Walczak; Iwona Misiuta; Svitlana Garbuzova-Davis; Lixian Jiang; Juan Sanchez-Ramos; Paul R Sanberg; Tanja Zigova; Alison E Willing
Journal:  Stem Cells       Date:  2005-08-04       Impact factor: 6.277

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.